The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
| Status: | Recruiting |
|---|---|
| Conditions: | Women's Studies |
| Therapuetic Areas: | Reproductive |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 3/14/2019 |
| Start Date: | January 15, 2019 |
| End Date: | March 2020 |
The Effect of 81mg vs 162mg ASA for Preeclampsia Prevention in Obese Women at High Risk for Developing Preeclampsia
Low dose aspirin (LDA) is used for preeclampsia (PE) prevention in high risk women, but the
precise mechanism and optimal dose is not known. Evidence in the non-obstetric literature
suggests AR may be more common among patients with a high body mass index (BMI). Recent
unpublished data showed that LDA substantially lowers TxB2 levels regardless of BMI, but
rates of complete platelet inhibition are lower in women with BMI ≥40. This data suggests
that higher doses of ASA may be necessary in obese women. Therefore we plan determine if use
of 162mg compared to the traditional 81mg ASA decreased rates of preeclampsia in women
considered high risk for developing preclampsia.
precise mechanism and optimal dose is not known. Evidence in the non-obstetric literature
suggests AR may be more common among patients with a high body mass index (BMI). Recent
unpublished data showed that LDA substantially lowers TxB2 levels regardless of BMI, but
rates of complete platelet inhibition are lower in women with BMI ≥40. This data suggests
that higher doses of ASA may be necessary in obese women. Therefore we plan determine if use
of 162mg compared to the traditional 81mg ASA decreased rates of preeclampsia in women
considered high risk for developing preclampsia.
Evidence suggests that an imbalance in prostacyclin and thromboxane A2 (TxA2) plays a key
role in PE. Aspirin (ASA) has a dose-dependent effect blocking production of TxA2, a potent
stimulator of platelet aggregation (PA) and promoter of vasoconstriction. Incomplete
inhibition of PA, designated aspirin resistance (AR), can be reduced by increasing the ASA
dose.
role in PE. Aspirin (ASA) has a dose-dependent effect blocking production of TxA2, a potent
stimulator of platelet aggregation (PA) and promoter of vasoconstriction. Incomplete
inhibition of PA, designated aspirin resistance (AR), can be reduced by increasing the ASA
dose.
Inclusion Criteria:
- BMI at enrollment >/= 30
- plan for ASA for preeclampsia prevention
Exclusion Criteria:
- BMI < 30
- already on ASA
We found this trial at
1
site
Columbus, Ohio 43210
Principal Investigator: Kara M Rood, MD
Phone: 440-321-0264
Click here to add this to my saved trials
